A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
A hacker group who claimed to be behind a cyber attack on Sony Pictures have posted a message online apparently mocking the FBI.
The returns of Benedict Cumberbatch's detective and the X Factor judge were among 2014's most tweeted TV moments in a billion conversations.
A family has issued an appeal to help find their missing pet turkey - in case he gets gobbled up as someone's Christmas dinner.